A comprehensive analysis of the impact of pseudomonas aeruginosa colonisation in adult bronchiectasis Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives Year: 2015
Pseudomonas aeruginosa isolates in bronchiectasis: Wath particulaties and risk factors? Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016
Aminoglycoside use for pseudomonas aeruginosa in bronchiectasis Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Patients with no cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa : Role of inhaled colistin Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014
Pseudomonas aeruginosa colonisation in patients without bronchiectasisSource: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura Year: 2014
Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016
Atorvastatin as novel treatment in bronchiectasis patients colonized with pseudomonas aeruginosa Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016
Genotypic studies of pseudomonas aeruginosa isolates from adult non-cystic fibrosis bronchiectasis patients Source: International Congress 2015 – Advances from translational research in respiratory infections Year: 2015
Role of stenotrophomonas maltophilia infection in CF pulmonary exacerbations Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013
Pseudomonas aeruginosa pneumonia in the communitySource: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014
Bacterial colonization in patients with bronchiectasis Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections Year: 2014
Pseudomonas aeruginosa from CF airways uses various strategies to outcompete staphylococcus aureus Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016
Pulmonary infections with pseudomonas aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 642s Year: 2004
Azithromycin therapy and pseudomonas aeruginosa isolation in a non-cystic fibrosis bronchiectasis cohort Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives Year: 2015
Nicotinamide and bacterial killing in patients with non-cystic fibrosis bronchiectasis Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Nontuberculous mycobacteria lung infection in bronchiectasis: Prevalence and clinical characteristics Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014
COPD and pseudomonas aeruginosa , an association Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections Year: 2014
Pseudomonas aeruginosa infections Source: Respipedia Article Year: 2018
Microbial aetiology and outcomes of CAP in bronchiectatic patients Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients Year: 2013
Exacerbations and pneumonia in bronchiectasis: Clinical and microbiological characterization Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook Year: 2015